. Abbreviations: 3V, third ventricle; 4V, fourth ventricle; 12N, hypoglossal nucleus; aca, anterior commissure (anterior); aci, anterior commissure (intrabulbar); Acb, accumbens nucleus; AD, anterodorsal thalamic nucleus; AHC, anterior hypothalamic area (central); AM, anteromedial thalamic nucleus; AOD, anterior olfactory nucleus (dorsal); AOL, anterior olfactory nucleus (lateral); AOM, anterior olfactory nucleus (medial); AON, anterior olfactory nucleus; APir, amygdalopiriform transitional area; ATg, anterior tegmental nucleus; Au, auditory cortex; AV, anteroventral thalamic nucleus; BLA, basolateral amygdaloid nucleus (anterior); BLP, basolateral amygdaloid nucleus (posterior); BLV, basolateral amygdaloid nucleus (ventral); BMP, basomedial amygdaloid nucleus (posterior); CA1, field CA1 of the hippocampus; CA3, field CA3 of the hippocampus; CbCx, cerebellar cortex; cc, corpus callosum; Cg, cingulate cortex; CPu, caudate putamen; D3V, dorsal 3 ventricle; DEn, dorsal endopiriform nucleus; DG, dentate gyrus; DR, dorsal raphe nucleus; DTT, dorsal tenia tecta; Ect, ectorhinal cortex; EP, entopeduncular nucleus; EPl, external plexiform layer of the olfactory bulb; FrA, frontal association cortex; Gl, glomerular layer of the olfactory bulb; GP, globus pallidus; GrDG, granule cell layer of the dentate gyrus; GrL, granule cell layer of the cerebellar cortex; GrO, granule cell layer of the olfactory bulb; Hi, hippocampus; I, insular cortex; IC, inferior colliculus; ICjM, islands of Calleja (Major); icp, inferior cerebellar peduncle; IG, indusium griseum; IO, inferior olive; IOD, inferior olive (dorsal nucleus); IODM, inferior olive (dorsomedial cell group); IOM, inferior olive (medial nucleus); IOPr, inferior olive (principal nucleus); Int, interposed cerebellar nuclei; IntP, interposed cerebellar nucleus (posterior); La, lateral amygdaloid nucleus; LaDL, lateral amygdaloid nucleus (dorsolateral); Lat, lateral cerebellar nuclei; LaVL, lateral amygdaloid nucleus (ventrolateral); LaVM, lateral amygdaloid nucleus (ventromedial); LEnt, lateral entorhinal cortex; LG, lateral geniculate nucleus; LS, lateral septal nucleus; LV, lateral ventricle; M1, primary motor cortex; M2, secondary motor cortex; MD, mediodorsal thalamic nucleus; me5, mesencephalic 5 tract; Me5, mesencephalic 5 nucleus; Med, medial cerebellar nucleus; MedDL, medial cerebellar nucleus (dorsolateral protruberance); Mi, Mitral cell layer of the olfactory bulb; MG, medial geniculate nucleus; ML, molecular layer of the cerebellar cortex; mlf, medial longitudinal fasciculus; MN, mammillary nuclei; MnR, median raphe nucleus; MoDG, molecular layer of the dentate gyrus; MS, medial septal nucleus; mt, mammillothalamic tract; O, orbital cortex; OB, olfactory bulb; ON, olfactory nerve; PaS, parasubiculum; PCL, Purkinje cell layer of the cerebellar cortex; Pir, piriform cortex; Pn, pontine nuclei; Po, posterior thalamic nucleus; PRh, perirhinal cortex; PT, paratenial thalamic nucleus; PtA, parietal association cortex; PrL, prelimbic cortex; PrS, presubiculum; Py, pyramidal tract; Rbd, rhabdoid nuclei; Rt, reticular thalamic nucleus; RS, retrosplenial cortex; S, subiculum; S1, primary somatosensory cortex; S2, secondary somatosensory cortex; SC, superior colliculus; SHi, septohippocampal nucleus; sm, stria medullaris of the thalamus; SNR, substantia nigra pars reticulata; sp5, spinal trigeminal tract; TeA, temporal association cortex; TS, triangular septal nucleus; Tu, olfactory tubercle; V1, primary visual cortex; V2L, secondary visual cortex (lateral area); V2M, secondary visual cortex (medial); VA, ventral anterior thalamic nucleus; VL, ventrolateral thalamic nucleus; VM, ventromedial thalamic nucleus; VP, ventroposterior thalamic nucleus; wm, white matter; xscp, decussation of the superior cerebellar peduncle. Fatty acid amide hydrolase (FAAH) is a membrane-associated enzyme that was first isolated from rat liver on account of its ability to catalyze hydrolysis of the sleepinducing lipid oleamide (Cravatt et al., 1995 (Cravatt et al., , 1996 . Analysis of the substrate selectivity of FAAH revealed, however, that it also hydrolyzes anandamide (arachidonoylethanolamide), a putative endogenous ligand for the CB 1 -type cannabinoid receptor in the brain (Cravatt et al., 1996) . 2-Arachidonylglycerol (2-AG), a second putative endocannabinoid, also appears to be reactive with FAAH in vitro (Goparaju et al., 1998) and therefore these data indicate that FAAH might be generally required for inactivation of endocannabinoids in the brain. Evidence in support of this was provided by the detection of FAAH in brain tissue and localization of FAAH expression in neurons of the rat brain (Cravatt et al., 1996; Giang and Cravatt, 1997; Thomas et al., 1997; Egertová et al., 1998; Tsou et al., 1998) . Moreover, recently mice lacking the FAAH gene have been generated and analysis of these animals has demonstrated that FAAH controls endogenous anandamide levels in the brain and attenuates the behavioral effects of exogenous anandamide (Cravatt et al., 2001 ). Interestingly, however, analysis of mice lacking FAAH indicates that FAAH is not responsible for regulating 2-AG in vivo (Lichtman et al., 2002) , and consistent with this idea, the enzyme monoglyceride lipase is now thought to be the main enzyme involved in inactivation of 2-AG in the brain (Dinh et al., 2002) .
The potential for FAAH to exert a regulatory influence on endocannabinoid signaling at a synaptic level has been investigated by using immunocytochemistry to compare the distribution of FAAH and the CB 1 receptor in selected regions of the rat brain (Egertová et al., 1998) . Importantly, FAAH is localized in the somata and dendrites of principal neurons in the cerebellar cortex (Purkinje cells), hippocampus (pyramidal cells) and the neocortex (pyramidal cells). Moreover, in each of these brain regions there is a complementary pattern of cannabinoid receptor expression, with CB 1 targeted to the axon terminals of neurons that are presynaptic to the FAAH-expressing principal cells. Detection of FAAH in the somato-dendritic compartment of neurons that are postsynaptic to CB 1 -expressing axons led us to propose a model of endocannabinoid signaling in which endocannabinoids are both synthesized and inactivated postsynaptically and function as retrograde synaptic messenger molecules that act on presynaptic CB 1 receptors to inhibit release of "classical" neurotransmitters (Egertová et al., 1998; Elphick and Egertová , 2001) .
Recently, several studies have demonstrated that endocannabinoids do indeed act as retrograde signals at synapses in the brain (reviewed in Maejima et al., 2001a; Wilson and Nicoll, 2002; Kreitzer and Regehr, 2002) . In particular, and Ohno-Shosaku et al. (2001) showed that endocannabinoids mediate a retrograde signal from depolarized hippocampal pyramidal cells to presynaptic GABAergic axon terminals that causes suppression of inhibitory input (depolarization-induced suppression of inhibition or DSI). Similarly, Kreitzer and Regehr (2001a) reported that depolarization-induced suppression of excitation (DSE) in the cerebellar cortex is mediated by a retrograde endocannabinoid signal from depolarized Purkinje cells to presynaptic glutamatergic parallel fibers. Because FAAH is expressed in neurons that generate endocannabinoids (e.g. hippocampal pyramidal cells and Purkinje cells; Egertová et al., 1998) , it is likely that this enzyme may influence the spatiotemporal dynamics of retrograde signaling by endocannabinoids.
To obtain a complete assessment of FAAH's potential role in the regulation of endocannabinoid signaling, we have performed an immunocytochemical analysis of FAAH and CB 1 expression throughout the mouse brain, using FAAH-knockout mice to establish unequivocally the specificity of FAAH-immunostaining in wild type animals. The detailed analysis of FAAH and CB 1 expression in the mouse brain that we present here provides a neuroanatomical framework that will facilitate use of the mouse as a model system for analysis of the physiological and behavioral roles of the endocannabinoid signaling system.
EXPERIMENTAL PROCEDURES
Preliminary immunocytochemical analysis of FAAH and CB 1 expression was performed using brains from mice of the BALB/c strain to establish working methods prior to analysis of brains from FAAH-knockout mice (FAAH Ϫ/Ϫ ) and their wild type littermates (FAAH ϩ/ϩ ). FAAH Ϫ/Ϫ and FAAH ϩ/ϩ mice were produced from intercrosses of 129SvJ-C57BL/6 FAAH ϩ/Ϫ mice at the Scripps Research Institute, as described by Cravatt et al. (2001) . Three pairs of mice were analysed at ages between 12 and 16 weeks: 680/681 (female, 16 weeks), 909/910 (male, 12 weeks) and 755/ 762 (female, 16 weeks). Mice were asphyxiated with CO 2 and perfused through the heart with 25 ml of 4% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.4, as approved by the Queen Mary, University of London Animal Care and Use Committee and by The Home Office (UK). Moreover, the experimental procedures used were designed to minimize the number of animals used and their suffering. Brains were removed and postfixed in Bouin's fixative for at least 3 days at room temperature before embedding in paraffin wax. Coronal and saggital sections (7 or 10 m) were cut using a Leica RM2145 microtome (Leica, Nussloch, Germany), and sets of adjacent sections were collected at 0.5 mm intervals through the brain and then mounted on glass slides coated with 2% gelatin (w/v) in chrome alum solution. Dewaxed sections were blocked with 3% normal goat serum/PBS with 0.2% Triton X-100 (PBST) and then incubated with previously characterized antibodies to a GST-fusion protein incorporating aminoacid residues 38 -579 of FAAH (Egertová et al., 1998 Cravatt et al., 2001) , and used here at a dilution of 1:100 in PBST. Bound antibodies were revealed using the ABC Elite kit (Vector Laboratories, Peterborough, UK). To enable comparison of FAAH expression with CB 1 cannabinoid receptor expression, series of brain sections adjacent to series that had been processed with FAAH antibodies were tested immunocytochemically with a previously characterized antiserum (2825.3) to the C-terminal tail of mouse/rat CB 1 at a dilution of 1:1000 (see Egertová et al., 1998) or with antibodies affinity-purified from the CB 1 -antiserum 2816.4 (see .
Low-magnification digital images ( Fig. 1 ) of the immunostained sections were captured using a Retiga 1300 12-bit monochrome camera (Qimaging Corp., Burnaby, B.C., Canada) linked to a Leica DMRA2 compound microscope (Leica, Nussloch, Germany). OpenLab 3.0.8 (Improvision) software was used to import images from the camera. High-magnification images (Figs. 2-9) of immunostained sections were captured using a Hamamatsu digital camera linked to a Leica DMRD microscope (Leica, Wetzlar, Germany). High Performance Image Control System (HiPic 32) software was used to import images from the camera. Digital images were processed using Adobe Photoshop software (version 5.5), removing imperfections caused by dust particles, and then labeled with reference to Paxinos and Franklin (2001) .
RESULTS

General observations
Immunocytochemical analysis of FAAH expression in sections of wild type mouse brain revealed a pattern of immunostaining ( Fig. 1 ) that was generally consistent with the distribution of FAAH mRNA expression in rat brain (Thomas et al., 1997) . Moreover, to establish unequivocally the specificity of the immunostaining observed with the FAAH antibodies in the mouse brain, we analyzed brain sections from FAAH Ϫ/Ϫ mice alongside brain sections from their wild type littermates. Importantly, all of the immunostaining seen in FAAH ϩ/ϩ mice with FAAH antibodies was absent in FAAH Ϫ/Ϫ mice, as illustrated in Fig. 2A and B, respectively. These findings demonstrate that the FAAH antibodies used in this study are specific for FAAH under immunocytochemical conditions, consistent with previous analysis of FAAH ϩ/ϩ mice and FAAH Ϫ/Ϫ mice (Cravatt et al., 2001) .
The majority of the FAAH-immunoreactivity in the mouse brain was associated with neuronal somata and their dendrites. However, in some regions of the brain FAAH-immunoreactive cells were also present in fiber tracts (white matter). This is consistent with the detection of signals for FAAH mRNA in white matter of the rat brain, as reported by Thomas et al. (1997) . The morphology of the FAAH-immunoreactive cells in fiber tracts of the mouse brain indicates that these cells are oligodendrocytes (see Fig. 8C ). Consistent with this hypothesis, FAAH-immunoreactivity is also evident in the myelin sheath surrounding the unstained axons of large neurons (Fig. 8C) . Accordingly, myelin sheath-associated FAAH probably accounts for FAAH-immunoreactivity associated with several discrete fiber tracts in several regions of the brain (e.g. see caudate putamen, CPu in Fig. 1C) .
In addition to neuronal and oligodendrocytic expression of FAAH, FAAH-immunoreactivity is also present in ependymal cells that line the ventricles of the mouse brain and this can be seen in the low magnification images of Fig. 1 but it is more clearly seen at a higher magnification in Fig. 7A . However, no CB 1 -immunoreactivity is associated with the FAAH-immunoreactivity in ependymal cells. A detailed analysis of this feature of FAAH expression in the mouse brain is beyond the scope of this paper but it will be discussed in detail in a subsequent paper that will focus specifically on the role of FAAH in the ventricular epithelium (Egertová et al., unpublished observations) .
Here, for the first time, we illustrate and compare the distribution of FAAH and CB 1 throughout the mouse brain based on our analysis of brains from wild type mice (BALB/c, nϭ3; 129SvJ-C57BL/6, nϭ3). Fig. 1 shows FAAH-immunostaining (A, C, E, G, I, K, M, O, Q) and CB 1 -immunostaining (B, D, F, H, J, L, N, P, R) in two series of adjacent coronal sections of the brain of a single female animal (no. 680; FAAH ϩ/ϩ ; 129SvJ-C57BL/6). The distance between consecutive sections in each series is approximately 1 mm. The images in Fig. 1 provide an overview of the distribution of FAAH and CB 1 in the mouse brain. Moreover, below we refer to the images in Fig. 1 when discussing in detail the distribution of FAAH and CB 1 in different regions of the brain. Because of the limitations of space, it is not feasible to describe and illustrate at high magnification the distribution of FAAH and CB 1 in all regions of the mouse brain. Previously, we have described in detail and illustrated the distribution of CB 1 in the rat brain . Here we have focused on FAAH, and below we describe in detail and illustrate at higher magnification than the images in Fig. 1 those regions of the brain where FAAH-expressing cells are particularly abundant (Figs. 2-9 ). Moreover, in those brain regions where both FAAH and CB 1 are expressed at high levels we also show corresponding images of CB 1 -immunoreactivity in sections adjacent to images of sections showing FAAH-immunoreactivity (Figs. 3-6 ).
Olfactory bulb and olfactory cortex
Inspection of Fig. 1A and B reveals that intense FAAHimmunoreactivity is evident in the olfactory bulb (OB; Fig.  1A ) compared with relatively low levels of CB 1 expression (Fig. 1B) . More specifically and most noteworthy, FAAH is particularly abundant in fibers of the olfactory nerve (ON) and in the olfactory glomeruli (Gl) (Fig. 2A) . FAAH-immunoreactivity is also evident in the somata and dendrites of mitral cells (Mi; Fig. 2A) , consistent with previous analysis of rat brain (Tsou et al., 1998) . Relatively weak FAAHimmunoreactivity can also be seen in the granule cell layer (GrO) of the olfactory bulb ( Fig. 2A) .
FAAH-immunoreactive neuronal somata are evident in the majority of the cortical olfactory regions that receive direct input from the olfactory bulbs. These include the anterior olfactory nucleus (AON; Figs. 1A, 3A), the piriform cortex (Pir; Figs. 1C, E, G, I; 3C), the tenia tecta (DTT; Figs. 1C; 3E) and the indusium griseum (IG; Fig. 1C, E) , and in all of these regions FAAH-immunoreactive neuronal somata are surrounded by a complementary network of CB 1 -immunoreactive fibers (Figs. 1B, D, F, H, J; 3B, D, F) . FAAH-immunoreactive neurons are not, however, evident in the olfactory tubercle, a region of the olfactory cortex that contains a fine meshwork of CB 1 -immunoreactive fibers in both mouse (not shown) and rat . 
Septum, amygdala and hippocampal formation
Neuronal FAAH-immunoreactivity was detected in the lateral septum (LS; Fig. 1E ) and the triangular septal nucleus (TS; Fig. 1G) with associated low-level expression of CB 1 (Fig. 1F, H) . FAAH-immunoreactive neuronal somata are also present throughout the basolateral complex of the amygdala, which includes the lateral (La), basolateral (BLA, BLV) and basomedial (BMP) nuclei (Figs. 1I; 4A) . In all of these nuclei the FAAH-immunoreactive neuronal somata are surrounded by CB 1 -immunoreactive fibers (Figs. 1J; 4B).
Consistent with previous analysis of the rat brain (Egertová et al., 1998) , FAAH-immunoreactivity was detected in the somata and dendrites of pyramidal cells throughout the hippocampus (Figs. 1I, K; 5A, E). In addition, however, FAAH-immunoreactivity is also evident in the somata of dentate gyrus granule cells (DG; Figs. 1I, K; GrDG; 5A, C). This is of particular interest because, although FAAH mRNA has been detected in these cells in the rat brain (Thomas et al., 1997) , FAAH-immunoreactivity is not evident in granule cells of the rat dentate gyrus (Tsou et al., 1998; our unpublished observations) . CB 1 -immunoreactivity was detected in a dense meshwork of fibers surrounding both hippocampal pyramidal cells (Figs.  1J, K ; 5B, F) and granule cells of the dentate gyrus (Figs.  1J, K ; 5B, D), respectively, as in the rat brain . (Fig. 6A) . CB 1 -immunoreactivity is present in a network of fibers in all layers but the density of these fibers is highest in layers II and III, the outer region of layer V and throughout layer VI with layers I, IV and V (inner) showing much sparser fiber staining (Fig. 6B) .
Cerebral cortex and cerebellar cortex
Consistent with previous analysis of the rat cerebellar cortex (Egertová et al., 1998) , FAAH-immunoreactivity was detected in the somata of Purkinje cells (PCL; Fig. 6E ). However, the dendritic branches of the Purkinje cells contained little or no FAAH-immunoreactivity. FAAH-immunoreactivity was also evident in the somata of granule cells (GrL), although the intensity of staining is quite weak (Fig.  6E) . This is consistent with the detection of FAAH mRNA in rat cerebellar granule cells (Thomas et al., 1997) , although in the rat FAAH-immunoreactivity is not evident in these cells (Egertová et al., 1998; Tsou et al., 1998) . As in rat brain, CB 1 -immunoreactivity was detected in the axon terminals of basket cells surrounding Purkinje cell somata and in a dense meshwork of fibers in the molecular layer (ML) surrounding Purkinje cell dendrites (Fig. 6F) . CB 1 -immunoreactivity in the molecular layer is largely associated with the parallel fibers of granule cells, consistent with CB 1 mRNA expression in granule-cell somata (Matsuda et al., 1993) . Fig. 7C ) and the medial geniculate (MG; 1K). Importantly, however, little or no CB 1 -immunoreactivity was detected in the thalamus (Fig. 1H, J) . This is consistent with the findings of Herkenham et al. (1991) who detected only low concentrations of cannabinoid-binding sites in thalamic nuclei of the rat brain. Thus, the thalamus represents a region of the brain where FAAH-immunoreactive neurons are particularly abundant but with few or no associated CB 1 -expressing fibers.
Mid-brain
FAAH-immunoreactive neurons are present in the inferior colliculus (IC; Figs. 1M; 8A), the superior colliculus (not shown), the rhabdoid nucleus (Rbd; Figs. 1M; 8B), several mesencephalic raphe nuclei (MnR, DR; Figs. 1M; 8B) and the mesencephalic trigeminal nucleus (Me5; Fig. 8C ). Little or no CB 1 -immunoreactivity is evident in these regions of the brain (Fig. 1L, N) . Conversely, FAAH-immunoreactive neurons were not evident, however, in the substantia nigra pars reticulata (SNR; Fig. 1K ), a region of the mid-brain that contains a very high concentration of CB 1 -immunoreactivity in both mouse (Fig. 1L ) and rat .
In the mid-brain, the expression of FAAH by oligodendrocytes is particularly striking. For example, in Fig. 8B FAAH-immunoreactive oligodendrocytes associated with fiber tracts (mlf; xscp) are abundant and more intensely stained than the FAAH-immunoreactive neurons in the raphe nuclei. Moreover, Fig. 8C shows a clear example of a FAAH-immunoreactive oligodendrocyte with a process that is continguous with FAAH-immunoreactive myelin sheath surrounding unstained axons in the mesencephalic trigeminal tract (me5).
Hind-brain
In the hind brain, in addition to FAAH-immunoreactivity associated with the cerebellar cortex (see above), FAAHimmunoreactive neurons are present in the hypoglossal nucleus (12N; Figs. 1Q; 9A) and the inferior olive (IO; Figs. 1Q; 9B), but little or no CB 1 -immunoreactivity was evident in these nuclei (Fig. 1R) . FAAH-immunoreactivity was also detected in the somata of neurons in the cerebellar nuclei (Figs. 1O; 9C), which receive synaptic input from Purkinje cell axons. In white matter surrounding the cerebellar nuclei, FAAH-immunoreactive oligodendrocytes are particularly abundant (Fig. 9C ) and Fig. 9C shows how much more intensely stained these glial cells are compared to neighbouring neurons. The cerebellar nuclei are, however, void of CB 1 -immunoreactivity (Fig. 1P) , consistent with the absence of cannabinoid-binding sites in these nuclei in the rat brain (Herkenham et al., 1991) .
DISCUSSION
Here we report the first detailed analysis of the distribution of FAAH in the mouse brain, using FAAH Ϫ/Ϫ mice as negative controls to provide an unequivocal determination of the specificity of immunostaining in wild type animals. The majority of FAAH in the mouse brain is associated with neurons and it is the presence of FAAH in neurons that is probably most directly relevant to endocannabinoid signaling, as discussed below. An interesting feature of neuronal FAAH-immunostaining in several regions of the brain was that FAAH-immunoreactivity appears not to be confined to neuronal somata but also extends into surrounding areas of neural tissue. This is most clearly seen in the hippocampal formation where, although the highest concentration of FAAH-immunoreactivity is clearly located in the somata of hippocampal pyramidal cells and granule cells of the dentate gyrus, there is also widespread immunostaining in adjacent layers that contain their axons and dendrites (Fig.  5A, C, E) . The diffuse and homogeneous nature of this staining suggests that it is not compartmentalized within neuronal processes but is located extracellularly. One possibility is that this putative extracellular FAAH-immunoreactivity is an artifact of tissue preparation resulting from lysis of FAAH-expressing neuronal somata. An alternative and more intriguing explanation, however, is that it reflects active secretion of FAAH (either in soluble or vesicleassociated form) into the surrounding extracellular medium by FAAH-expressing neurons. Probably the most striking and intensely stained FAAH-immunoreactive neurons of the entire mouse brain were to be found in the mesencephalic trigeminal nucleus (Me5), as shown in Fig. 8C . These neurons are of particular interest because they are functionally homologous to sensory neurons of the dorsal root ganglia and they are the only primary sensory neurons with cell bodies located within the central nervous system (Holstege et al., 1995) . Physiologically these neurons are involved in mediating jaw opening and closing reflexes and it will therefore be of specific interest to investigate the functional significance of FAAH expression in their somata.
In addition to neuronal FAAH expression, FAAH is also expressed by oligodendrocytes and ventricular ependymal cells of the mouse brain. The functional significance of FAAH expression in these non-neuronal cells is not yet known and therefore this study represents the starting point for a new aspect of FAAH research. The association of FAAH with oligodendrocytes in fiber tracts is, however, of particular interest with respect to a recent study showing that FAAH activity in the striatum is reduced in a rat model of Parkinson's disease in which inputs to the striatum from the substantia nigra are disrupted (Gubellini et al., 2002) . We speculate that the loss of neuronal inputs to the striatum from the substantia nigra may also lead to loss of associated FAAH-expressing oligodendrocytes, which could account for the reduced levels of striatal FAAH in rats with experimental Parkinsonism.
To address the main objective of this study and assess the potential role of FAAH in endocannabinoid signaling, we have compared the distribution of FAAH with that of the CB 1 cannabinoid receptor throughout the mouse brain. We have identified: (1) regions of the brain where FAAH is expressed with little or no associated CB 1 ; (2) regions of the brain where there is expression of both FAAH and CB 1 ; and (3) regions of the brain where CB 1 is expressed with little or no associated FAAH. Below we will consider the functional significance of these findings and, in particular, the potential role of FAAH in regulation of the spatiotemporal dynamics of retrograde signaling by endocannabinoids.
Regions of the brain where FAAH-expressing neurons are present but accompanied by few or no CB 1 -expressing fibers include the thalamus, mid-brain and hind brain. In some brain regions (e.g. hypoglossal nucleus, median raphe nucleus), the absence of CB 1 -immunoreactivity may simply reflect insensitivity of the immunocytochemical methods used here because there is evidence for the presence of low-level cannabinoid receptor expression from radioligand binding studies (Herkenham et al., 1991) . However, there clearly are some regions of the brain (e.g. thalamic nuclei, mesencephalic trigeminal nuclei, cerebellar nuclei) where FAAH-immunoreactive neurons are widespread but in the absence of associated CB 1 expression. In regions of the brain such as these, the role of FAAH is likely to be unrelated to CB 1 -dependent endocannabinoid signaling mechanisms. Intriguingly, it is possible that in these regions of the brain, FAAH participates in regulation of signaling mediated by a novel G protein coupled anandamide receptor discovered recently in the brains of CB 1 Ϫ/Ϫ mice (Breivogel et al., 2001) . Alternatively, in these regions of the brain FAAH may be involved in inactivation of fatty acid amide signaling molecules that exert their effects via non-cannabinoid receptors. For example, there is evidence that oleamide exerts effects in the thalamus via allosteric interaction with the serotonin 5-HT 7 receptor (Thomas et al., 1999) and the presence of FAAH in thalamic neurons may regulate the actions of this sleep-inducing lipid.
More typically, however, FAAH and CB 1 are anatomically associated, with FAAH-immunoreactive neuronal somata surrounded by CB 1 -immunoreactive fibers, as reported previously in the rat cerebellar cortex, hippocampus and neocortex (Egertová et al., 1998) . Based on this anatomical relationship between FAAH and CB 1 expression, we predicted that endocannabinoids may act as retrograde signaling molecules at synapses in the brain (Egertová et al., 1998; Elphick and Egertová , 2001 ) and experimental studies on the hippocampus and cerebellar cortex have proved that this hypothesis was correct (Kreitzer and Regehr, 2001a,b; Maejima et al., 2001a,b; Ohno-Shosaku et al., 2001; ). Therefore, it seems likely that endocannabinoids may also act as retrograde messengers at synapses in the many regions of the brain that we describe here where "complementary" expression of FAAH and CB 1 occurs, which include the olfactory cortex, amygdala, dentate gyrus, transitional cortex and neocortex. Moreover, it is important to consider how FAAH may influence the dynamics of retrograde signaling by endocannabinoids at synapses.
In analyzing the spatial dynamics of retrograde signaling by endocannabinoids in the hippocampus, conclude that their effects are restricted to a sphere with a diameter of about 40 m surrounding the pyramidal cell to which a depolarizing stimulus has been applied. Moreover, Carlson et al. (2002) have found that release of endocannabinoids by a pyramidal cell causes a normally ineffective train of excitatory post-synaptic currents to induce long-term potentiation (LTP) in that cell but not in neighbouring cells. Because FAAH is located in the somata and dendrites of hippocampal pyramidal cells, the activity of this enzyme is likely to be a key determinant of the distance over which endocannabinoids diffuse from a cellular site of synthesis before being inactivated. Thus, the presence of FAAH in pyramidal cell somata may confine endocannabinoid-facilitated LTP to cells in which endocannabinoid biosynthesis has been triggered. Moreover, FAAH probably exerts such a regulatory role in the spatial dynamics of retrograde signaling by endocannabinoids not only in the hippocampus but also in the many regions of the brain that we describe here where FAAH is located in neuronal somata and/or dendrites surrounded by CB 1 -immunoreactive fibers. For example, a complementary pattern of FAAH and CB 1 expression like that seen in the hippocampus is also evident in the cortex of the forebrain and in subcortical regions such as the amygdala. Accordingly, several recent studies indicate that endocannabinoids also act as retrograde synaptic signaling molecules in these regions of the forebrain (Katona et al., 2001; Trettel and Levine, 2002) .
FAAH is likely to influence not only the spatial dynamics of cannabinoid signaling but also the temporal dynamics. Evidence for such a role is apparent in the cerebellar cortex where endocannabinoids mediate retrograde suppression of both excitatory and inhibitory synapses onto Purkinje cells (Kreitzer and Regehr, 2001a,b; Maejima et al., 2001b) . Here FAAH is located in Purkinje cell somata, whilst CB 1 is located on the presynaptic terminals of granule cells (glutamatergic parallel fibers), basket cells (GABAergic) and probably also climbing fibers (glutamatergic). Depolarization of Purkinje cells causes transient endocannabinoid-mediated inhibition of excitatory inputs from parallel fibers and climbing fibers with maximal inhibition occurring after approximately 5 s, followed by a gradual restoration of basal excitatory input within 50 s (Kreitzer and Regehr, 2001a) . Because FAAH is located in the somato-dendritic compartment of Purkinje cells, the duration of the inhibitory action of Purkinje cell-derived endocannabinoids is likely to be largely influenced by uptake and FAAH-mediated inactivation of endocannabinoids in Purkinje cells.
Importantly, the dynamics of retrograde endocannabinoid signaling may be influenced not only by the presence of FAAH in the somata of neurons that are postsynaptic to CB 1 -expressing fibers but also by the expression of FAAH by other nearby cells. For example, in the cerebellar cortex the presence of FAAH in the somata of granule cells may influence the dynamics of retrograde signaling from the principal cells (Purkinje cells) to the presynaptic terminals of parallel fibers, climbing fibers and basket cells. Conversely, in the olfactory bulb, retrograde endocannabinoid signaling may operate at the synapses between CB 1 -immunoreactive projection neurons from the anterior olfactory nucleus and FAAH-immunoreactive granule cells. However, the dynamics of cannabinoid signaling may also be influenced by the presence of FAAH in principal cells of the olfactory bulb (mitral cells). Moreover, in mouse olfactory bulbs FAAH is also present in fibers of the olfactory nerves that project into the olfactory bulb glomeruli where they form synapses with the glomerular dendrites of mitral cells. This is of particular interest because it is the first example, to the best of our knowledge, where FAAH is targeted to the axonal compartment of neurons because in all other regions of the mouse and rat brain it is targeted to the somato-dendritic compartment of neurons. It also provides a unique example of a synapse where FAAH is located both presynaptically (olfactory-receptor neuron terminals) and postsynaptically (mitral cells). The functional significance of this complex pattern of expression is not yet clear, but it may reflect the unusual synaptic organization of olfactory glomeruli (see Shepherd and Greer, 1998) .
The distribution of CB 1 in the brain, although strikingly complementary with FAAH in many regions of the forebrain and in the cerebellar cortex, is not always associated with FAAH-expressing neurons. For example, there is a population of striatal GABAergic medium-spiny projection neurons that target the CB 1 receptor to their axonal terminals in globus pallidus (GP), entopeduncular nucleus (EP) and substantia nigra pars reticulata (SNR). The density of CB 1 receptors in these output nuclei is particularly high (Fig. 1H, J, L) , whilst FAAH-expressing neurons are sparse or absent (Fig. 1G, I , K). This may in part simply reflect the neuroarchitecture of these brain regions, but nevertheless it is of interest to consider the mechanisms of cannabinoid signaling at striatal output synapses. A recent study by Wallmichrath and Szabo (2002) demonstrated that cannabinoids inhibit release of GABA by striatonigral axons and, moreover, depolarization of SNR neurons causes endocannabinoid-mediated suppression of GABAergic inhibitory postsynaptic currents. These data indicate that endocannabinoids mediate retrograde signaling from SNR neurons to the presynaptic CB 1 -expressing axons of striatonigral neurons. Interestingly, because SNR neurons do not appear to express FAAH, the dynamics of retrograde endocannabinoid signaling at these synapses may be different to synapses where FAAH is expressed postsynaptically (e.g. hippocampal pyramidal cells) and further experimental analysis is now required to address this issue.
In conclusion, this study provides a neuroanatomical basis for future investigations of endocannabinoid signaling at synapses in many regions of the brain. In particular, our data suggest that the dynamics of endocannabinoid signaling may be directly influenced by the occurrence and relative abundance of FAAH in neurons. Moreover, the identification of FAAH-immunoreactive neurons without associated CB 1 cannabinoid receptor expression may pave the way for functional analysis of fatty acid amide signaling pathways mediated by other receptors.
